ZURICH (Reuters) - The U.S. Food and Drug Administration has accepted Novartis unit Sandoz's regulatory submission for approval of a biosimilar copy of Amgen's blockbuster Enbrel drug, the Swiss ...
Sandoz has filed an antitrust lawsuit in the US against Amgen, challenging alleged anti-competitive practices surrounding the biologic blockbuster Enbrel (etanercept). Filed at the US District Court ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback